This knowledge is essential for understanding the basic nature of CD8+ T cell repertoire formation, and supports cancer immunotherapy design by aiding the identification of TCRs that target patient‐specific neoantigens, although CD8+ T cell activation goes beyond the complex αβTCR recognition of peptide‐HLA‐I complexes [1, 15, 16]. This evidence concerns the gene CD8A and cancer.